ANALYSIS: Teva takes it step by step in Brazil
This article was originally published in Scrip
Executive Summary
While Teva is known as a generics giant in most markets, in Brazil things are different. Here the firm is more active as an innovator, although not for want of trying to make its mark in the Brazilian generics space. The firm talked to Scrip about its step by step approach and why this challenging market is still worth the trouble.